|Slideshows|August 12, 2019

Focus on Bipolar Disorder: 6 New Studies

Treatment failure risk is high, new biomarker of conversion from major depressive disorder, depression stifles creativity, and other recent findings are summarized here.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

New Analysis of BXCL501 At-Home Administration Shows Reduction of Agitation in Bipolar and Schizophrenia

ByJessica Walters

May 29th 2026

The Significant Presence of Comorbidities in Bipolar Depression: Insights From Mark Zimmerman, MD

ByMark Zimmerman, MD

May 27th 2026

Bipolar Disorder With Mixed Features: Recognition and Treatment, With Roger McIntyre, MD, at APA

ByJessica Walters

May 20th 2026

New Data From IMPACT-TD Registry: Only 23% of Young Adults With Mood Disorders and Tardive Dyskinesia Symptoms Are Formally Diagnosed

ByLeah Kuntz

May 18th 2026

Decision-Making and Risk Assessment in Perinatal Psychopharmacology

ByVeerle Bergink, MD

May 17th 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Focus on Bipolar Disorder: 6 New Studies

Related Content

New Analysis of BXCL501 At-Home Administration Shows Reduction of Agitation in Bipolar and Schizophrenia

The Significant Presence of Comorbidities in Bipolar Depression: Insights From Mark Zimmerman, MD

Bipolar Disorder With Mixed Features: Recognition and Treatment, With Roger McIntyre, MD, at APA

New Data From IMPACT-TD Registry: Only 23% of Young Adults With Mood Disorders and Tardive Dyskinesia Symptoms Are Formally Diagnosed

Decision-Making and Risk Assessment in Perinatal Psychopharmacology

Latest CME

Southern California Psychiatry Conference

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Trending on Psychiatric Times

FDA Issues CRL for CTx-1301 for Treatment of ADHD

Insights Into Mechanism-Based Biomarkers for Psychosis Prediction from Kim Do, PhD

New Name, New Path for Psychiatry: The Future of the DSM

Nonpharmacological Augmentation of Ketamine, Neuroplasticity, and Behavioral Therapy

Endangered Education: Psychiatric Professional Degrees Under Attack